Phase II study of neoadjuvant S-1 concurrent radiotherapy for borderline resectable pancreatic cancer
Phase 2
Recruiting
- Conditions
- borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000009172
- Lead Sponsor
- JASPAC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)no prior fluoropyrimidine anticancer therapy 2)prior abdominal radiotherapy 3)diarrhea 4)iodine contrast allergy 5)pulmonary fibrosis or interstitial pneumonitis 6)ascites or pleural effusion 7)active infection 8)poor controlled diabetes 9)active other malignancy 10)active digestive ulcer 11)serious complications 12)continuous steroid administration 13)severe mental disorder 14)pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method curative R0 resection rate
- Secondary Outcome Measures
Name Time Method overall survival, recurrence free survival, response rate, pathological response rate, 2 year survival rate, adverse event, surgical complication, response rate based on the central radiological diagnosis